White Papers

The Opioid Crisis: A Lesson in Adaptation

Posted October 17, 2017| Tanya Chotibut

There is an over-reliance on opioid medications within the U.S., with alarming increases in diversion, overdose, and addiction and it has created the opioid epidemic.

As it stands now, opioid analgesics are the most commonly prescribed class of medications in the United States with more than 30 percent of Americans suffering from some form of acute or chronic pain.  

This whitepaper outlines the opioid epidemics and the related issues for pharma companies while offering a high-level solution for pharma companies to consider as they move products through the life-cycle. Solutions are not limited to post-marketing surveillance and implementing adaptive trials with more data integration and the use of predictive analytics.

Download the Whitepaper:

Tags: , , , ,

Related Resources

Read More

Exploring the Impact of COVID-19 on Strategy, Insights and Intelligence Professionals

Fuld + Company surveyed Strategy, Insights, and Intelligence (SI&I) professionals to better understand how the Covid-19 pandemic and associated economic […]

Read More

Fuld + Company’s Initial Perspectives on the Impact of Covid-19: Emerging Opportunities Across Industries

After several weeks of observing and examining the actions of businesses, government and other participants in the U.S economy, Fuld […]

Read More

2019 Pharma Companies to Watch Report

This proprietary qualitative analysis identifies five top pharmaceutical companies that stand out as major disruptors. Fuld + Company’s analysis includes […]

Subscribe to our mailing list for our latest updates: